BSE: BLISSGVS CMP: Rs 530.35 P/E: 43.01x ROCE: 16.77% 6M Ret: +224.32% Div Yld: 0.28% ATH: Rs 541.75
Key Performance Indicators
Bliss GVS Pharma trades at Rs 530.35 on BSE (BLISSGVS), with a market capitalisation of Rs 5618.42 crore. The price-to-earnings ratio is 43.01x. Return on capital employed stands at 16.77%. The six-month return is +224.32%. Quarterly net profit is Rs 37.00 crore (+128.90% year-on-year change). Quarterly sales stand at Rs 256.99 crore (+29.80% year-on-year). The dividend yield is 0.28%. The all-time high is Rs 541.75, 2.1% above the current price.
Highlights
Bliss GVS Pharma has delivered a six-month return of 224.32%, with a market capitalisation of Rs 5618.42 crore at the current price of Rs 530.35. The all-time high of Rs 541.75 sits 2.1% above the current price, indicating the stock has corrected from its historical peak and offers headroom for appreciation toward that level. The company's ROCE of 16.77% — above the 15% quality threshold, indicating the business generates meaningful returns above the cost of capital — is a key distinguishing fundamental metric.
The P/E of 43.01x carries a moderate growth premium relative to the Indian market average, pricing in above-economy earnings growth expectations. The dividend yield of 0.28% provides a meaningful income component — a signal of cash generation capability and management's willingness to return capital. The healthcare sector tailwinds — rising health insurance penetration, growing chronic disease burden, and government healthcare investment — provide structural support for sustained revenue and earnings growth.
Business Overview
Bliss GVS Pharma manufactures and exports specialty pharmaceutical formulations — particularly suppositories, pessaries, and other unique dosage forms — to regulated markets in Africa, Southeast Asia, and other emerging market geographies. Suppository and pessary formulations for antimalarial, antifungal, and reproductive health therapeutic categories are the company's core specialisation. This niche is defended by the technical complexity of manufacturing temperature-sensitive dosage forms and the established distribution relationships required for success in African regulated markets.
The quarterly profit of Rs 37.00 crore growing 128.90% on revenue of Rs 256.99 crore growing 29.80% shows strongly accelerating growth. The P/E of 43.01 times, dividend yield of 0.28%, and ROCE of 16.77% describe a premium-valued specialty pharma exporter with improving fundamentals. The six-month return of 224.32% — the highest in this batch — and the all-time high of Rs 541.75 — just Rs 11.40 above the current price of Rs 530.35 — confirm the stock is very close to its historical ceiling, with sustained near-term momentum.
Financial Analysis
Bliss GVS Pharma's most recent quarterly financial results show revenue of Rs 256.99 crore (+29.80% year-on-year) and net profit of Rs 37.00 crore (128.90% year-on-year variation). The triple-digit profit growth rate substantially outpaces revenue growth — a pattern that signals meaningful margin expansion, operating leverage taking effect, or non-recurring income contribution that should be verified through the quarterly results commentary.
The ROCE of 16.77% is the primary quality indicator for this business. At 16.77%, the business crosses the threshold that Warren Buffett famously cited as a hallmark of exceptional businesses — generating returns on capital substantially above typical cost of capital levels, creating economic value with each rupee reinvested.
At Rs 5618.42 crore — a mid-cap company with growing institutional visibility — Bliss GVS Pharma is at the scale where institutional investors are beginning to build meaningful positions, creating a potential re-rating catalyst as coverage broadens.
Investor Highlights
The investment case for Bliss GVS Pharma rests on the combination of a 16.77% ROCE — indicating a capital-efficient business with sustainable competitive advantages — and a demonstrated revenue and earnings growth trajectory that supports the current P/E of 43.01x. The combination of solid ROCE with consistent earnings growth creates a compounding engine where both business scale and per-share earnings grow simultaneously, supporting share price appreciation over a full investment cycle.
With the current price 2.1% below the all-time high of Rs 541.75, there is established headroom toward the historical peak. If fundamental performance continues to deliver quarterly profit growth and improving ROCE, the stock has a reference target for re-rating toward the all-time high level.
The dividend yield of 0.28% provides a foundational income return that is independent of capital appreciation — a meaningful characteristic for investors who value income alongside growth. A dividend-paying company with a positive ROCE above 15% is distributing cash it does not need for reinvestment at attractive rates, implying the business generates more cash than its optimal reinvestment requirements. Investors should access the company's latest annual report and quarterly results on the BSE/NSE portal for current financial data and management commentary on the growth outlook.
Frequently Asked Questions
Q: What does Bliss GVS Pharma do and why has it delivered a 224.32% six-month return?
A: Bliss GVS Pharma operates in India's healthcare sector. The 224.32% six-month return reflects a combination of sector-level tailwinds, improving quarterly financial performance — quarterly profit growing 128.90% and revenue growing 29.80% year-on-year — and market re-rating of the company's growth and quality profile. Specific business details and catalysts are documented in BSE/NSE exchange filings.
Q: What does the ROCE of 16.77% indicate about Bliss GVS Pharma's business quality?
A: Bliss GVS Pharma's ROCE of 16.77% measures pre-tax profit generated per rupee of total capital employed. At 16.77%, the business consistently generates returns above the typical cost of capital for Indian companies — a hallmark of businesses with durable competitive advantages, whether from technology, relationships, scale, or regulatory positioning. Tracking ROCE over multiple quarters provides a leading indicator of business quality improvement or deterioration.
Q: How does the P/E of 43.01x compare to fundamentals for Bliss GVS Pharma?
A: The P/E of 43.01x should be assessed in conjunction with the earnings growth rate and ROCE. At 43.01x, the stock carries a moderate premium relative to the market average of 20–25x, compensated in part by the ROCE of 16.77% and the quarterly earnings growth of 128.90%.
Q: What is Bliss GVS Pharma's all-time high and how far is the current price from it?
A: Bliss GVS Pharma's all-time high is Rs 541.75. The current price of Rs 530.35 is 2.1% below the all-time high, offering potential headroom for appreciation if fundamental performance supports continued market re-rating. The all-time high provides a reference ceiling that informs sentiment and potential price target discussion, though fundamental value — determined by earnings, ROCE, and growth — is the primary determinant of sustainable price levels.
Q: Where can investors access Bliss GVS Pharma's official financial data and disclosures?
A: Bliss GVS Pharma's quarterly results, annual reports, investor presentations, shareholding patterns, and all material corporate announcements are filed with BSE and are freely accessible through the exchange filing portals at nseindia.com and bseindia.com. SEBI listing regulations mandate timely disclosure of all financial results and material developments. These filings are the primary source of verified financial and operational data for investment analysis.